|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> effects on extracellular flux via glycolysis and mitochondrial stress tests suggest that candidate compounds 3 and 9 disrupt glycolysis and OxPhos efficiently in MCT1 expressing colorectal adenocarcinoma WiDr and MCT4 expressing triple negative breast cancer MDA-MB-231 cells.
|
31040927 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
|
17483329 |
2007 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT4 protein expression was upregulated (P < 0.0001) in ccRCC and showed significant association with cancer-related death.
|
23881922 |
2013 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
|
25497091 |
2014 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
|
25497091 |
2014 |
|
Malignant neoplasm of stomach stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
|
27224918 |
2016 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MCT-4, directly mediated by HIF-1α, maintains a high level of glycolysis, and the enhanced glycolysis promotes pro-inflammatory properties, which are involved in arsenite carcinogenesis.
|
28419250 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter 4 (MCT-4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer.
|
29113201 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter 4 (MCT-4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer.
|
29113201 |
2017 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
MCT-4 protein expression was significantly associated with depth of invasion (P=0.034).
|
29113201 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MCT4 is a marker of tumor-associated stroma in neoplastic tissue.
|
29248132 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
|
29483215 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies.
|
30051648 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer.
|
30211114 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate transporter 4 (MCT4) is a membrane transporter of monocarboxylates that has been reported to play an important role in tumorigenesis and progression in several solid tumor types.
|
30226548 |
2018 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.
|
31217781 |
2019 |
|
Hamartoma Syndrome, Multiple
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
|
Cortical cataract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate transporter 4 (MCT4) is an H<sup>+</sup>-coupled symporter highly expressed in metastatic tumors and at inflammatory sites undergoing hypoxia or the Warburg effect.
|
31719150 |
2019 |
|
NONAKA MYOPATHY
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A 24 hours treatment with 1,25(OH)2D3 (100 nM) significantly increased cytosolic pH (pHi), significantly decreased Na+/H+ exchanger activity, NHE1 and MCT4 transcript levels as well as protein abundance and significantly increased lactate concentration in the supernatant.
|
28222424 |
2017 |
|
Atherosclerotic lesion
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
A passage number- and atherosclerotic lesion-dependent methylation pattern of MCT3 was demonstrated in the CpG island located in exon 2.
|
16116050 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A survival curve analysis indicated that high MCT-4 expression in lung AC was associated with a decreased overall survival rate (P=0.001).
|
29113201 |
2017 |